Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CXCR2 | P25025 | 3/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24872545 | 0.83 | KDM4E (0.42) | ALDH1A1KDM4EHPGDHSD17B10KMT2A | |
| SCHEMBL22904392 | 0.80 | CXCL8 (0.44) | ALDH1A1HPGDKMT2APOLBL3MBTL1 | |
| SCHEMBL7861381 | 0.80 | KDM4E (0.40) | ALDH1A1KDM4EHPGDHSD17B10KMT2A | |
| SCHEMBL20838005 | 0.80 | KDM4E (0.44) | ALDH1A1KDM4EHPGDHSD17B10KMT2A | |
| SCHEMBL10891656 | 0.80 | KDM4E (0.40) | ALDH1A1KDM4EHPGDHSD17B10KMT2A | |
| SCHEMBL16949914 | 0.80 | KDM4E (0.40) | ALDH1A1KDM4EHPGDHSD17B10KMT2A | |
| SCHEMBL12648426 | 0.80 | ALDH1A1 (0.44) | ALDH1A1KDM4EHPGDHSD17B10KMT2A | |
| SCHEMBL16953179 | 0.80 | S1PR1 (0.42) | ALDH1A1KDM4EHPGDHSD17B10KMT2A | |
| SCHEMBL29893592 | 0.79 | HPGD (0.40) | ALDH1A1KDM4EHPGDKMT2ATDP1 | |
| SCHEMBL837981 | 0.79 | HPGD (0.40) | ALDH1A1KDM4EHPGDKMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059163-A1 | FUSED RING COMPOUNDS | GENENTECH INC (US) | 2025-02-20 | — | — | US | disclosed |
| EP-4483881-A2 | FUSED RING COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2025-01-01 | — | — | EP | disclosed |
| EP-3735299-B1 | FUSED RING COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2024-10-02 | — | — | EP | disclosed |
| US-12084429-B2 | Fused ring compounds | GENENTECH, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| CN-118084866-A | Condensed ring compound | 豪夫迈·罗氏有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-118084867-A | Condensed ring compound | 豪夫迈·罗氏有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-118084870-A | Condensed ring compound | 豪夫迈·罗氏有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-118084868-A | Condensed ring compound | 豪夫迈·罗氏有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-112105419-B | Condensed ring compound | 豪夫迈·罗氏有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-20230089126-A1 | FUSED RING COMPOUNDS | GENENTECH INC (US) | 2023-03-23 | — | — | US | disclosed |
| EP-3066100-B1 | (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AS INHIBITORS OF FIBRINOLYSIS | Bayer Pharma AG (DE) | 2019-04-17 | — | — | EP | disclosed |
| US-20180344739-A1 | (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-12-06 | — | — | US | disclosed |
| US-10098883-B2 | (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-10-16 | — | — | US | disclosed |
| CN-105683194-B | The inhibitor of (azepine) pyrido PyrazolopyrimidinonecGMP and indazole hepyramine as fibrinolysis | 拜耳制药股份公司 | 2018-09-14 | — | — | CN | disclosed |
| US-20170239251-A1 | (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-08-24 | — | — | US | disclosed |
| US-9598417-B2 | (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-03-21 | — | — | US | disclosed |
| EP-3066100-A1 | (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AS INHIBITORS OF FIBRINOLYSIS | Bayer Pharma Aktiengesellschaft (DE) | 2016-09-14 | — | — | EP | disclosed |
| CN-105683194-A | (aza)pyridopyrazolopyrimidinones and indazolopyrimidinones as inhibitors of fibrinolysis | 拜耳制药股份公司 | 2016-06-15 | — | — | CN | disclosed |
| WO-2015067549-A1 | (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AS INHIBITORS OF FIBRINOLYSIS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-05-14 | — | — | WO | disclosed |
| US-20150126449-A1 | (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180344739-A1 | (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AND THEIR USE | SERPINB6, SERPINC1, SERPINE1 | ALDH1A1 212/4885KDM4E 2701/4885HPGD 83/4885 |
| US-20230089126-A1 | FUSED RING COMPOUNDS | KRAS, NRAS, HRAS | ALDH1A1 3258/4885KDM4E 3124/4885HPGD 2966/4885 |
| US-12084429-B2 | Fused ring compounds | KRAS, NRAS, HRAS | ALDH1A1 3258/4885KDM4E 3124/4885HPGD 2966/4885 |
| US-20250059163-A1 | FUSED RING COMPOUNDS | KRAS, NRAS, HRAS | ALDH1A1 3258/4885KDM4E 3124/4885HPGD 2966/4885 |
| US-20150126449-A1 | (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use | SERPINB6, SERPINC1, SERPINE1 | ALDH1A1 212/4885KDM4E 2701/4885HPGD 83/4885 |
| US-20170239251-A1 | (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AND THEIR USE | SERPINB6, SERPINC1, SERPINE1 | ALDH1A1 212/4885KDM4E 2701/4885HPGD 83/4885 |
| US-10098883-B2 | (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use | SERPINB6, SERPINC1, SERPINE1 | ALDH1A1 212/4885KDM4E 2701/4885HPGD 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.